Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-07-12
2011-07-12
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S174100
Reexamination Certificate
active
07976842
ABSTRACT:
The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.
REFERENCES:
patent: 2005/0009097 (2005-01-01), Better et al.
patent: 2005/0180979 (2005-08-01), Peters et al.
patent: 2010/0150918 (2010-06-01), Kufer et al.
patent: WO 2005/080428 (2005-09-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Rudikoff et al(Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979).
Pascalis et al (The Journal of Immunology (2002) 169, 3076-3084).
Casset et al. (2003) BBRC 307, 198-205.
Edwards et al., “Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer,”Cancer Res., 46 (3): 1306-1317, 1986.
Gastl et al., “Ep-CAM overexpression in breast cancer as a predictor of survival,”Lancet, 356 (9246): 1981-1982, 2000.
Int. Search Report and Written Opinion, issued in Int. App. No. PCT/EP2007/001127, dated Jun. 26, 2007.
Naundorf et al., “In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment,”Int. J. of Cancer, 100 (1): 101-110, 2002.
Prang et al., “Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines,”British J of Cancer, 382 (2): 342-349, 2005.
Raum et al., “Anti-self antibodies selected from a human IgD heavy chain repertoire: A novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens,”Cancer Immunology and Immunotherapy, 50 (3): 141-150, 2001.
Spizzo et al., “Prognostic significance of Ep-CAM and Her-2
eu overexpression in invasive breast cancer,”Int. J. Cancer, 98 (6): 883-888, 2002.
Tandon et al., “Association of the 323/A3 Surface Glycoprotein with Tumor Characteristics and Behavior in Human Breast Cancer,”Cancer Res., 50: 3317-3324, 1990.
Braun et al., “Monoclonal antibody therapy with Edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow,”Clinical Cancer Research, 5:3999-4004, 1999.
Office Communication, issued in Russian Patent Application No. 2008130963/15(038524), dated Nov. 26, 2010. (English translation).
Office Communication, issued in European Patent Application No. 07 703 377.7, dated Jun. 28, 2010.
Response to Office Communication issued in European Patent Application No. 07 703 377.7, submitted Dec. 20, 2010.
Reinhardt Carsten
Saller Robert
Fulbright & Jaworski
Huff Sheela J
Micromet AG
LandOfFree
Treatment of metastatic breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of metastatic breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of metastatic breast cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629252